Business Wire

Seoul Semiconductor: The #1 in Patent Power Pre-empting the Future with 2nd Generation LED Technologies


Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a global optical semiconductor company, announced that Seoul Semiconductor and Seoul Viosys (hereafter referred to as Seoul) are Korea's #1 optical semiconductor (LED) companies and are among the world's #1 patent-powered companies.

This press release features multimedia. View the full release here:

To view this piece of content from, please give your consent at the top of this page.

Global LED market share as per market research firm OMDIA in 2022 (Graphic: Business Wire)

Seoul is ranked first in the world in the ultraviolet (UV) LED field, developing and mass-producing these LEDs. It is ranked third in the visible-light LED category for the past two years. Its visible-light LEDs are widely used in lighting, displays, and automobiles. Seoul is on the path to being ranked #1.

Seoul is the only company in the world to offer the entire wavelength range from visible light to ultraviolet and infrared, in light-emitting diodes as well as laser diodes (VCSEL). In addition, Seoul is 100% vertically integrated with production capacity for all of these technologies: from wafers and chips to packages and modules.

Seoul is investing nearly $100 million in R&D every year and pouring out innovative LED technologies at a staggering rate. Its collection of patents is unrivaled in the LED industry.

Regarding technology patents, there are thousands of patents for applications related to other major industries. Almost none of the LED products in the world today can be produced unless Seoul approves the use of its patents.

Ready to leap to be #1 in the world with innovative 2nd generation technologies

LEDs recently sold on the market require a patent of Seoul for that enables 10,000+ hours of lifetime, the efficiency of 150 lm/W, and high-quality color quality (CRI 90+). Since Seoul’s founder CH Lee started the company 30 years ago, he has worked tirelessly alongside his teams (and still is today) to develop a collection of patents that protects these new technologies and his company’s future. Although we are not all created equal, CH Lee wants to show that there is hope and fair opportunity in the patent system for young people.

Lighting: good sleep, good memory, good eye health

Since the birth of the earth 4.5 billion years ago, the string of life has evolved under the influence of Sun’s light. As a result, our human body operates on a 24-hour basis following the cycle of the sun. In the morning sunlight, the body releases the serotonin hormone to raise awareness. It releases the melatonin hormone under the influence of early evening sunlight to help us sleep. A good night's sleep removes waste from the brain, strengthens memory, and helps our body recover.

Many LED lighting products today produce a significant amount of blue light. This light makes it harder to fall asleep and sleep more deeply. In addition, exposure to excessive blue light can lead to myopia in children.

Seoul has conducted experiments with various institutions across the globe to prove the amazing benefits of SunLike. These studies confirmed that SunLike lighting prevents myopia, and improves sleep and working memory. This research was conducted by the Center for Clinical Investigation (CCI) at Brigham and Women's Hospital at Harvard University in the U.S, University of Basel in Switzerland, Seoul National University in Korea, and SERI Ophthalmology Institute in Singapore. For more information, visit Seoul Semiconductor's website (

Automotive: WICOP LED Technology is required for communication by autonomous vehicles

For the safety of drivers and pedestrians, Vehicle to Everything (V2X) lighting technology recognizes and communicates with surrounding objects and is essential for self-driving cars. To realize V2X lighting technology, a new concept of WICOP technology with a robust structure without wires is essential. WICOP is already being adopted by nearly 10 percent in the headlights of top-brand cars in Europe, the U.S, and Korea, and is becoming the standard for all LEDs.

Displays: Ultra-high-definition micro and mini LED from TV to Tablet

Mini LEDs are used to increase the quality of LCDs, and WICOP LEDs that do not require existing wires are essential to use micro LEDs for wearable devices such as future watches and AR/VRs. WICOP was introduced to the world in 2015 by CH Lee to the global press at the Intercontinental Hotel in Shanghai, China. Today, this technology is adopted in nearly 20% of all displays. Seoul is the world's #1 player in Display.

Besides vaccines and other medical treatments, we need to find ways to prevent the virus from spreading. As newly mutated viruses continue to emerge, it is time for a fundamental solution to prevent the virus from entering the human body other than vaccines or treatments.

Some of Seoul’s most recent studies have shown that Violeds technology kills 99% of Delta and Omicron variants in just one second. During the same experiment, a reduction in the number of viruses in the air was confirmed for more than 90% within 20-30 minutes, which can lead to significantly lower infection rates. For more information about this and other studies, please visit the Seoul Viosys’ website(

CH Lee’s commitment and philosophy to technology development

CH Lee believes that in developed countries where patents are respected, industries develop more and people live better lives. The 18th-century industrial revolution lowered the poverty rate from 85% to 3% or less, and the infant mortality rate from 43% to 3%. The spread of the availability of electricity and the Internet decreased the illiteracy rate. Thus, information became universally accessible and eventually improved human rights. More importantly, the patent system brings 'fair opportunity' and creates a society with a little more hope.

It angers CEO Lee that there are still two-faced patent infringers prevalent who emphasize environmental, social, and corporate governance while selling obviously infringed products by changing labels or who are willing to buy infringing products for a cheap price. By defending his IP vigorously, he wants to give young people hope that fairness does exist. He will not cut his hair to show his fighting spirit and at the least encourage young people to keep their fighting spirit up as well.

About Seoul Semiconductor

Seoul Semiconductor is the world’s second-largest global LED manufacturer, a ranking excluding the captive market, and has more than 10,000 patents. Based on a differentiated product portfolio, Seoul offers a wide range of technologies, and mass produces innovative LED products for indoor and outdoor lighting, automotive, IT products, such as mobile phones, computer displays, and other applications, as well as the UV area. The company’s world’s first development and mass production products are becoming the LED industry standard and leading the global market with a package-free LED, WICOP; a high-voltage AC-driven LED, Acrich; an LED with 10X the output of a conventional LED, nPola; a cutting edge ultraviolet clean technology LED, Violeds; an all-direction light emitting technology, filament LED; a natural sun spectrum LED, SunLike; and more. For more information, please visit

To view this piece of content from, please give your consent at the top of this page.

Contact information

Seoul Semiconductor Co., Ltd.
Jinseop Jung
Tel: +82-70-4391-8555

About Business Wire

Business Wire
Business Wire

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY ® (fremanezumab)24.6.2022 18:54:00 CEST | Press release

Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Europe BV.1 These findings further offer insight into the treatment of migraine in real-world clinical practice. The interim findings were presented by Faisal Mohammad Amin, Associate Professor of Neurology at the University of Copenhagen, Denmark. Out of the total planned 1100 patients in PEARL, 389 patients are included in the interim analysis presented. These findings show that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more, over the six-month period from the start of treatment. Addit

Brigade-M3 European Acquisition Corp. 2021 Annual Report24.6.2022 16:59:00 CEST | Press release

Brigade-M3 European Acquisition Corp. (the “Company”), a special purpose acquisition company that was incorporated on 21 April 2021 under the laws of the Cayman Islands as an exempted company with limited liability and is listed on Euronext Amsterdam, today published its annual report for the period 21 April 2021 to 31 December 2021. The full report can be downloaded from the Company’s website via the following link: IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does n

PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop24.6.2022 16:41:00 CEST | Press release

PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. This press release features multimedia. View the full release here: PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. (Photo: Business Wire) News of the partnership was shared at an event hosted by 10KTF last night in New York. Their event was one of many hosted during the week of NFT.NYC, a conference attended by crypto industry professionals, traders, and other web3 enthusiasts. The official announcement confirms weeks of speculation after PUMA tw

Suzano outlines ESG milestone achievements and commitments at second annual ESG call24.6.2022 16:14:00 CEST | Press release

Suzano, the world’s largest hardwood pulp producer, today held its second annual ESG Call centered around its ambition to be a ‘regenerative company for a regenerative society’. Today’s ESG Call spotlighted measurable progress and ambitions across three core areas of action: climate change, biodiversity and social development. On Climate Change, the ACT initiative of the French Government and CDP scored Suzano ahead of its pulp and paper industry peers in virtually every metric. In 2021, Suzano brought forward its target for removing 40 million tons of carbon dioxide from the atmosphere from 2030 to 2025 which is being achieved through improvements to its industrial processes, such as systematically replacing the use of fossil fuels at its industrial plants with biomass, and through conversion of degraded land. As part of the company’s social commitments, Suzano launched a target in 2020 to lift 200,000 people out of poverty. This is more than pertinent, given that in Brazil, 10% of th

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)24.6.2022 15:38:00 CEST | Press release

Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that CRYSVITA® (burosumab) be approved for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with less than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom